FEROZ Pharmaceuticals: Major
Health Technology
328.26 -1.95%
Mkt Cap
14.6B
P/E (TTM)
14.87
EPS (TTM)
22.51
ROE (TTM)
7.64%
Div Yield
1.22%
Ferozsons Laboratories Limited (FEROZ) Financial Statements, Ratios & Dividends
About
Ferozsons Laboratories Ltd. is a holding company, which engages in the manufacture and sale of pharmaceuticals and other related products. It operates through the following segments: Ferozsons, BF Biosciences, and Others. The Ferozsons segment is involved in the import, manufacture, and sale of pharmaceutical products as well as the distribution of medical devices. The BF Biosciences segment includes the development and provision of pharmaceutical products. The Others segment focuses on offering pharmaceutical and other related products. The company was founded on January 28, 1954 and is headquartered in Lahore, Pakistan.
Financial Highlights
| FY2026 | FY2025 | ||
|---|---|---|---|
| Revenue | 23.96B | 18.86B | |
| Gross Profit | 10.31B | 7.63B | |
| Net Income | 978.58M | 776.54M | |
| EPS | 22.51 | 17.86 | |
| ROE | 7.64% | 6.58% | |
| ROA | 3.81% | 3.31% | |
| Gross Margin | 43.02% | 40.45% | |
| Net Margin | 4.08% | 4.12% | |
| Current Ratio | 1.87 | 1.94 | |
| DPS | 5.50 | 4.00 | |
| Free Cash Flow | -1.15B | 235.05M |
| FY2026 | FY2025 | ||
|---|---|---|---|
| Total Revenue | 23.96B | 18.86B | |
| Cost of Goods Sold | -13.65B | -11.23B | |
| Gross Profit | 10.31B | 7.63B | |
| SG&A Expenses | -7.91B | -5.64B | |
| Depreciation | -996.55M | -915.61M | |
| Other Operating Expense | -76.33M | -70.67M | |
| Total Operating Expense | -21.64B | -16.94B | |
| Operating Income (EBIT) | 2.32B | 1.92B | |
| Interest Income | 11.15M | 25.35M | |
| Interest Expense | -410.86M | -568.46M | |
| Equity in Earnings | 0 | 0 | |
| Other Non-Operating Income | 94.20M | 138.99M | |
| Total Non-Operating Income | -305.47M | -394.05M | |
| Pre-Tax Income | 2.02B | 1.53B | |
| Income Tax | -788.89M | -603.48M | |
| Minority Interest | -249.15M | -145.17M | |
| Net Income | 978.58M | 776.54M | |
| EBITDA | 3.34B | 2.85B | |
| EPS (Basic) | 22.51 | 17.86 | |
| EPS (Diluted) | 22.51 | 17.86 | |
| Gross Margin | 43.02% | 40.45% | |
| Operating Margin | 9.69% | 10.18% | |
| EBITDA Margin | 13.96% | 15.13% | |
| Pre-Tax Margin | 8.42% | 8.09% | |
| Net Margin | 4.08% | 4.12% |
| FY2026 | FY2025 | ||
|---|---|---|---|
| Profitability | |||
| Return on Equity (ROE) | 7.64% | 6.58% | |
| Return on Assets (ROA) | 3.81% | 3.31% | |
| Return on Invested Capital | 6.86% | 5.73% | |
| Gross Margin | 43.02% | 40.45% | |
| Operating Margin | 9.69% | 10.18% | |
| EBITDA Margin | 13.96% | 15.13% | |
| Net Margin | 4.08% | 4.12% | |
| Pre-Tax Margin | 8.42% | 8.09% | |
| Liquidity | |||
| Current Ratio | 1.87 | 1.94 | |
| Quick Ratio | 0.61 | 0.89 | |
| Leverage | |||
| Debt / Equity | 0.32 | 0.35 | |
| Debt / Assets | 0.16 | 0.17 | |
| LT Debt / Equity | 0.09 | 0.13 | |
| LT Debt / Assets | 0.05 | 0.07 | |
| Net Debt | 3.19B | 1.87B | |
| Total Debt | 4.25B | 4.29B | |
| Efficiency | |||
| Asset Turnover | 0.93 | 0.80 | |
| Inventory Turnover | 1.67 | 1.86 | |
| Per Share | |||
| Book Value Per Share | 304.56 | 284.69 | |
| Tangible Book Per Share | 304.22 | 284.05 | |
| Cash Per Share | 24.52 | 55.74 | |
| Total Debt Per Share | 97.81 | 98.74 | |
| Working Capital Per Share | 149.69 | 143.69 | |
| Shares & Market | |||
| Total Shares Outstanding | 43,469,052 | 43,469,052 | |
| Market Cap | 17.53B | 16.94B | |
| Enterprise Value | 23.06B | 20.90B | |
| Employees | 1,676 | 1,556 | |
| Shareholders | 3,862 | 3,862 | |
| FY2026 | FY2025 | ||
|---|---|---|---|
| Dividends Per Share | 5.50 | 4.00 | |
| Dividend Yield | 1.36% | 1.03% | |
| Payout Ratio | 24.43% | 22.39% | |
| Total Dividends Paid | -167.94M | -127.80M |
| FY2026 | FY2025 | ||
|---|---|---|---|
| P/E Ratio | 17.91 | 21.81 | |
| P/B Ratio | 1.32 | 1.37 | |
| P/S Ratio | 0.73 | 0.90 | |
| P/CF Ratio | 602.92 | 18.85 | |
| EV/EBITDA | 6.89 | 7.32 | |
| Market Cap | 17.53B | 16.94B | |
| Enterprise Value | 23.06B | 20.90B |
| TTM | ||
|---|---|---|
| Income | ||
| Revenue | 23.96B | |
| Gross Profit | 10.69B | |
| Operating Income | 2.45B | |
| Net Income | 978.58M | |
| EBIT | 2.45B | |
| Free Cash Flow | -1.15B | |
| EPS (Basic) | 22.51 | |
| Margins | ||
| Gross Margin | 44.62% | |
| Operating Margin | 10.25% | |
| Net Margin | 4.08% | |
| Returns | ||
| Return on Equity (ROE) | 7.64% | |
| ROIC | 0.07% | |
| Coverage & Debt | ||
| Interest Coverage | 5.9x | |
| Dividend Coverage | 14.37 | |
| Debt / Revenue | 0.18 | |
| Valuation & Scores | ||
| P/E (TTM) | 14.87 | |
| Sloan Ratio | 2.63 | |
| Zmijewski Score | -2.24 | |
Computed Metrics (Latest Period)
| FY2026 | ||
|---|---|---|
| Extended Returns | ||
| Return on Common Equity | 7.64% | |
| Return on Tangible Equity | 7.65% | |
| Return on Tangible Assets | 3.82% | |
| Return on Total Capital | 12.03% | |
| ROCE | 12.47% | |
| Growth | ||
| EPS Diluted Growth | 0.26% | |
| Sustainable Growth Rate | 5.77% | |
| Quality & Risk Scores | ||
| Piotroski F-Score | 7 | |
| Zmijewski Score | -2.24 | |
| Sloan Ratio | 2.63 | |
| Valuation (Computed) | ||
| Graham Number | 392.77 | |
| Tobin's Q Ratio | 0.67 | |
| Leverage & Coverage | ||
| Interest Coverage | 5.7x | |
| Total Debt / Capital | 0.24% | |
| Assets / Equity (Leverage) | 1.99 | |
| Net Debt / EBITDA | 0.95 | |
| Effective Interest Rate | 9.62% | |
| Debt / Revenue | 0.18 | |
| Efficiency (Computed) | ||
| Fixed Asset Turnover | 2.06 | |
| Receivables Turnover | 8.79 | |
| Dividends (Computed) | ||
| Payout Ratio | 0.24% | |
| Dividend Coverage | 14.37 | |
| Share Buyback Ratio | 0.00 | |
| Per Employee | ||
| Revenue / Employee | 14.29M | |
| Net Income / Employee | 583.9K | |
| Oper. Income / Employee | 1.39M | |
| Total Assets / Employee | 15.69M | |
| Balance Sheet (Computed) | ||
| Tangible Assets | 26.28B | |
| Invested Capital | 14.49B | |
| Working Capital | 6.51B | |
| Book Value Per Share | 304.56 | |
| Earnings Schedule | ||